Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy

Robert Davis, David Eastman, Heather McPhillips, Marsha A. Raebel, Susan E. Andrade, David Smith, Marianne Ulcickas Yood, Sascha Dublin, Richard Platt

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: Calcium channel blockers and beta-blockers (BBs) are widely used during pregnancy, but data on their safety for the developing infant are scarce. We used population-based data from 5 HMOs to study risks for perinatal complications and congenital defects among infants exposed in-utero. Methods: We studied women older than 15 years delivering an infant between 1/1/96 and 12/31/00, who had been continuously enrolled with prescription drug coverage for ≥1 year prior to delivery. Information on prescription drug dispensings, inpatient, and outpatient diagnoses and procedures was obtained from automated databases at each HMO. Results: There were 584 full-term infants exposed during pregnancy to BBs and 804 full-term infants exposed to calcium-channel blockers, and over 75000 unexposed mother-infant pairs with ≥30 days follow-up. Infants exposed to BBs in the third trimester of pregnancy had over threefold increased risk for hypoglycemia (RR 3.1; 95% CI 2.2, 4.2) and an approximately twofold increased risk for feeding problems (RR 1.8; 95% CI 1.3, 2.5). Infants exposed to calcium-channel blockers in the third trimester had an increased risk for seizures (RR 3.6 95% CI 1.3, 10.4). Chart review confirmed the majority of the exposed seizure and hypoglycemia cases. There were no increased risks for congenital anomalies among either group of infants, except for the category of upper alimentary tract anomalies; this increased risk was based on only two exposed cases. Conclusions: Infants whose mothers receive BBs are at increased risk for neonatal hypoglycemia, while those whose mothers take calcium-channel blockers are at increased risk for neonatal seizures.

Original languageEnglish (US)
Pages (from-to)138-145
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Calcium Channel Blockers
Pregnancy
Hypoglycemia
Seizures
Prescription Drugs
Health Maintenance Organizations
Mothers
Third Pregnancy Trimester
Inpatients
Outpatients
Databases
Safety

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Pharmacology (medical)

Cite this

Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. / Davis, Robert; Eastman, David; McPhillips, Heather; Raebel, Marsha A.; Andrade, Susan E.; Smith, David; Yood, Marianne Ulcickas; Dublin, Sascha; Platt, Richard.

In: Pharmacoepidemiology and Drug Safety, Vol. 20, No. 2, 01.02.2011, p. 138-145.

Research output: Contribution to journalArticle

Davis, Robert ; Eastman, David ; McPhillips, Heather ; Raebel, Marsha A. ; Andrade, Susan E. ; Smith, David ; Yood, Marianne Ulcickas ; Dublin, Sascha ; Platt, Richard. / Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. In: Pharmacoepidemiology and Drug Safety. 2011 ; Vol. 20, No. 2. pp. 138-145.
@article{69752b0c04284daf9dbd591d87057f10,
title = "Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy",
abstract = "Purpose: Calcium channel blockers and beta-blockers (BBs) are widely used during pregnancy, but data on their safety for the developing infant are scarce. We used population-based data from 5 HMOs to study risks for perinatal complications and congenital defects among infants exposed in-utero. Methods: We studied women older than 15 years delivering an infant between 1/1/96 and 12/31/00, who had been continuously enrolled with prescription drug coverage for ≥1 year prior to delivery. Information on prescription drug dispensings, inpatient, and outpatient diagnoses and procedures was obtained from automated databases at each HMO. Results: There were 584 full-term infants exposed during pregnancy to BBs and 804 full-term infants exposed to calcium-channel blockers, and over 75000 unexposed mother-infant pairs with ≥30 days follow-up. Infants exposed to BBs in the third trimester of pregnancy had over threefold increased risk for hypoglycemia (RR 3.1; 95{\%} CI 2.2, 4.2) and an approximately twofold increased risk for feeding problems (RR 1.8; 95{\%} CI 1.3, 2.5). Infants exposed to calcium-channel blockers in the third trimester had an increased risk for seizures (RR 3.6 95{\%} CI 1.3, 10.4). Chart review confirmed the majority of the exposed seizure and hypoglycemia cases. There were no increased risks for congenital anomalies among either group of infants, except for the category of upper alimentary tract anomalies; this increased risk was based on only two exposed cases. Conclusions: Infants whose mothers receive BBs are at increased risk for neonatal hypoglycemia, while those whose mothers take calcium-channel blockers are at increased risk for neonatal seizures.",
author = "Robert Davis and David Eastman and Heather McPhillips and Raebel, {Marsha A.} and Andrade, {Susan E.} and David Smith and Yood, {Marianne Ulcickas} and Sascha Dublin and Richard Platt",
year = "2011",
month = "2",
day = "1",
doi = "10.1002/pds.2068",
language = "English (US)",
volume = "20",
pages = "138--145",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy

AU - Davis, Robert

AU - Eastman, David

AU - McPhillips, Heather

AU - Raebel, Marsha A.

AU - Andrade, Susan E.

AU - Smith, David

AU - Yood, Marianne Ulcickas

AU - Dublin, Sascha

AU - Platt, Richard

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Purpose: Calcium channel blockers and beta-blockers (BBs) are widely used during pregnancy, but data on their safety for the developing infant are scarce. We used population-based data from 5 HMOs to study risks for perinatal complications and congenital defects among infants exposed in-utero. Methods: We studied women older than 15 years delivering an infant between 1/1/96 and 12/31/00, who had been continuously enrolled with prescription drug coverage for ≥1 year prior to delivery. Information on prescription drug dispensings, inpatient, and outpatient diagnoses and procedures was obtained from automated databases at each HMO. Results: There were 584 full-term infants exposed during pregnancy to BBs and 804 full-term infants exposed to calcium-channel blockers, and over 75000 unexposed mother-infant pairs with ≥30 days follow-up. Infants exposed to BBs in the third trimester of pregnancy had over threefold increased risk for hypoglycemia (RR 3.1; 95% CI 2.2, 4.2) and an approximately twofold increased risk for feeding problems (RR 1.8; 95% CI 1.3, 2.5). Infants exposed to calcium-channel blockers in the third trimester had an increased risk for seizures (RR 3.6 95% CI 1.3, 10.4). Chart review confirmed the majority of the exposed seizure and hypoglycemia cases. There were no increased risks for congenital anomalies among either group of infants, except for the category of upper alimentary tract anomalies; this increased risk was based on only two exposed cases. Conclusions: Infants whose mothers receive BBs are at increased risk for neonatal hypoglycemia, while those whose mothers take calcium-channel blockers are at increased risk for neonatal seizures.

AB - Purpose: Calcium channel blockers and beta-blockers (BBs) are widely used during pregnancy, but data on their safety for the developing infant are scarce. We used population-based data from 5 HMOs to study risks for perinatal complications and congenital defects among infants exposed in-utero. Methods: We studied women older than 15 years delivering an infant between 1/1/96 and 12/31/00, who had been continuously enrolled with prescription drug coverage for ≥1 year prior to delivery. Information on prescription drug dispensings, inpatient, and outpatient diagnoses and procedures was obtained from automated databases at each HMO. Results: There were 584 full-term infants exposed during pregnancy to BBs and 804 full-term infants exposed to calcium-channel blockers, and over 75000 unexposed mother-infant pairs with ≥30 days follow-up. Infants exposed to BBs in the third trimester of pregnancy had over threefold increased risk for hypoglycemia (RR 3.1; 95% CI 2.2, 4.2) and an approximately twofold increased risk for feeding problems (RR 1.8; 95% CI 1.3, 2.5). Infants exposed to calcium-channel blockers in the third trimester had an increased risk for seizures (RR 3.6 95% CI 1.3, 10.4). Chart review confirmed the majority of the exposed seizure and hypoglycemia cases. There were no increased risks for congenital anomalies among either group of infants, except for the category of upper alimentary tract anomalies; this increased risk was based on only two exposed cases. Conclusions: Infants whose mothers receive BBs are at increased risk for neonatal hypoglycemia, while those whose mothers take calcium-channel blockers are at increased risk for neonatal seizures.

UR - http://www.scopus.com/inward/record.url?scp=78751699545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751699545&partnerID=8YFLogxK

U2 - 10.1002/pds.2068

DO - 10.1002/pds.2068

M3 - Article

VL - 20

SP - 138

EP - 145

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 2

ER -